{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:43:03Z","timestamp":1791477783257,"version":"4.3.4"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Gilead Sciences Inc."}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,3,24]]},"abstract":"<jats:p>\n            Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are prodrugs of the HIV-1 nucleotide reverse transcriptase inhibitor tenofovir (TFV).\n            <jats:italic>In vivo<\/jats:italic>\n            , TAF achieves &gt;4-fold-higher intracellular levels of TFV diphosphate (TFV-DP) compared to TDF. Since thymidine analog-associated mutations (TAMs) in HIV-1 confer reduced TFV susceptibility, patients with TAM-containing HIV-1 may benefit from higher TFV-DP levels delivered by TAF. Moreover, the presence of the M184V mutation increases TFV susceptibility during TDF- or TAF-based therapy.\n          <\/jats:p>","DOI":"10.1128\/aac.02557-19","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T09:48:26Z","timestamp":1579772906000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V"],"prefix":"10.1128","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0911-4237","authenticated-orcid":false,"given":"Nicolas","family":"Margot","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Ram","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Abram","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haubrich","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Callebaut","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV","author":"The Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2018","unstructured":"The Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. 2018. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. DHHS\/National Institutes of Health, Bethesda, MD. http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf."},{"key":"e_1_3_3_3_2","volume-title":"Guidelines, version 9.1 (English)","author":"European AIDS Clinical Society","year":"2018","unstructured":"European AIDS Clinical Society. 2018. Guidelines, version 9.1 (English). European AIDS Clinical Society, Brussels, Belgium."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2008.10.071"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2479983"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304223281605"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix015"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000166098.54564.0c"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.05.012"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/381784"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000225"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60616-X"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.12.5653"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00816-06"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2266"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2018.03.012"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/314560"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.47.11.3478-3484.2003"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.47.11.3377-3383.2003"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1205"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh009"},{"key":"e_1_3_3_22_2","volume-title":"International AIDS Conference","author":"Perez-Valero I","year":"2018","unstructured":"Perez-Valero I, Llibre JM, Lazzarin A, di Perri G, Pulido F, Molina JM, Esser S, McNicholl IR, Lorgeoux RP, Margot N, Shao Y, Piontkowsky D, Das M, Haubrich R. 2018. A phase 3b open-label pilot study to evaluate switching to elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (E\/C\/F\/TAF) single-tablet regimen in virologically suppressed HIV-1 infected adults harboring the NRTI resistance mutation M184V and\/or M1841 (GS-US-292\u20131824): week 24 results, presentation TUAB0104. International AIDS Conference, Amsterdam, the Netherlands."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001193"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv131.79"},{"key":"e_1_3_3_25_2","volume-title":"HIV Glasgow 2016","author":"Callebaut C","year":"2016","unstructured":"Callebaut C. 2016. Resistance profile analysis of treatment-experienced HIV-1-infected patients switching to elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (E\/C\/F\/TAF) plus darunavir (DRV), presentation. HIV Glasgow 2016, Glasgow, United Kingdom."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.12.2781"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074163"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0091-679x(08)60600-7"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.12.008"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2017.0248"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02557-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02557-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:33:33Z","timestamp":1645486413000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02557-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,3,24]]}},"alternative-id":["10.1128\/AAC.02557-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02557-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"assertion":[{"value":"2019-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02557-19"}}